WO2012178196A3 - Protection against dengue virus and prevention of severe dengue disease - Google Patents

Protection against dengue virus and prevention of severe dengue disease Download PDF

Info

Publication number
WO2012178196A3
WO2012178196A3 PCT/US2012/044071 US2012044071W WO2012178196A3 WO 2012178196 A3 WO2012178196 A3 WO 2012178196A3 US 2012044071 W US2012044071 W US 2012044071W WO 2012178196 A3 WO2012178196 A3 WO 2012178196A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
protection against
dengue
severe
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/044071
Other languages
French (fr)
Other versions
WO2012178196A2 (en
Inventor
Sujan Shresta
Lauren Yauch
Alessandro Sette
Daniela Weiskopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Original Assignee
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/041889 external-priority patent/WO2011163628A2/en
Application filed by La Jolla Institute for Allergy and Immunology filed Critical La Jolla Institute for Allergy and Immunology
Priority to EP12801934.6A priority Critical patent/EP2723372A4/en
Priority to US14/128,268 priority patent/US20150150960A1/en
Publication of WO2012178196A2 publication Critical patent/WO2012178196A2/en
Publication of WO2012178196A3 publication Critical patent/WO2012178196A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides uses, methods and compositions for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-Dengue virus T cell response in a subject.
PCT/US2012/044071 2010-06-24 2012-06-25 Protection against dengue virus and prevention of severe dengue disease Ceased WO2012178196A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP12801934.6A EP2723372A4 (en) 2011-06-24 2012-06-25 PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE FORMS OF DENGUE
US14/128,268 US20150150960A1 (en) 2010-06-24 2012-06-25 Protection against dengue virus and prevention of severe dengue disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/041889 WO2011163628A2 (en) 2010-06-24 2011-06-24 Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
USPCT/US2011/041889 2011-06-24

Publications (2)

Publication Number Publication Date
WO2012178196A2 WO2012178196A2 (en) 2012-12-27
WO2012178196A3 true WO2012178196A3 (en) 2013-03-28

Family

ID=47424845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/044071 Ceased WO2012178196A2 (en) 2010-06-24 2012-06-25 Protection against dengue virus and prevention of severe dengue disease

Country Status (2)

Country Link
EP (1) EP2723372A4 (en)
WO (1) WO2012178196A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986071B1 (en) 2012-01-24 2014-02-28 Biomerieux Sa METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
EP2959915A1 (en) * 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
CN115804362A (en) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 IFN-alpha/beta R -/- Injection for enhancing infection of mice by antibody dependency and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009469A1 (en) * 2002-02-26 2004-01-15 Maxygen, Inc. Patent Department Novel flavivirus antigens
US20110033449A1 (en) * 2006-10-20 2011-02-10 Martin John Glennie Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23578A1 (en) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech VIRUS CAPSID PROTEIN DENGES INDUCTIVE PROTECTION RESPONSE AND VACCINE COMPOSITION
WO2011163628A2 (en) * 2010-06-24 2011-12-29 La Jolla Institute For Allergy And Immunology Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009469A1 (en) * 2002-02-26 2004-01-15 Maxygen, Inc. Patent Department Novel flavivirus antigens
US20110033449A1 (en) * 2006-10-20 2011-02-10 Martin John Glennie Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2723372A4 *

Also Published As

Publication number Publication date
EP2723372A2 (en) 2014-04-30
WO2012178196A2 (en) 2012-12-27
EP2723372A4 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
EP3736282C0 (en) CELL-PENETRATING PEPTIDE, CONJUGATE COMPRISING THEM, AND COMPOSITION COMPRISING THE CONJUGATE
WO2011072099A3 (en) Compositions and methods comprising protease variants
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
HK1209785A1 (en) Compositions and methods comprising a lipolytic enzyme variant
BR112015001838A2 (en) efflux inhibitor compositions and treatment methods using the same.
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
WO2012024632A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e
BRPI0822337A2 (en) Folates, compositions and uses thereof
WO2014052836A3 (en) Methods and compositions for treating infection
EP2899201A4 (en) CELLULAR PENETRATION PEPTIDE COMPRISING THE SAME, AND COMPOSITION COMPRISING THE CONJUGATE
WO2012129341A3 (en) Disease detection in plants
WO2010102052A3 (en) Methods of inhibiting photoreceptor apoptosis
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
WO2013106689A8 (en) Hcv ns3 protease inhibitors
WO2011098778A3 (en) Peptides for vaccines against birch allergy
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
EP2931310A4 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
ZA201304439B (en) Anti-regurgitation and/or anti-gastro-oesophageal reflux composition,preparation and uses
WO2013029011A8 (en) Methods and compositions comprising a c-terminal bax peptide
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
WO2012048115A3 (en) Polypeptides and their use in treating and limiting respiratory syncytial virus infection
WO2012138731A3 (en) Activated nucleoside analog conjugates and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12801934

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012801934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14128268

Country of ref document: US